On February 18, 2019 Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK (Press release, Exicure, FEB 18, 2019, View Source;p=RssLanding&cat=news&id=2387769 [SID1234533371]). Dr. Giljohann’s presentation titled "Spherical Nucleic Acids: Clinical Progress" will occur on Wednesday, February 20, 2019 at 9:10 am GMT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 18, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its fourth quarter and full year 2018 financial results on Monday, March 4, 2019 (Press release, BioCryst Pharmaceuticals, FEB 18, 2019, View Source [SID1234533373]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 1271286. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 1271286.

On February 18, 2019 Physicians’ Education Resource (PER), a leading resource for continuing medical education (CME), reported that it will host the 2019 New York GU: 12th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies meeting on March 15 and 16 at The Westin New York at Times Square in New York City (Press release, Physicians’ Education Resource, FEB 18, 2019, View Source [SID1234533374]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This dynamic prostate cancer congress will be co-chaired by Daniel P. Petrylak, M.D., professor of medicine and urology, co-director of the Signal Transduction Research Program, Yale Cancer Center, and Leonard G. Gomella, M.D., FACS, the Bernard W. Godwin, Jr. professor of prostate cancer; chairman, department of urology, Jefferson Medical College; clinical director and senior director for clinical affairs, Jefferson Kimmel Cancer Center Network.

"We look forward to presenting our New York GU meeting again this year," said Phil Talamo, president of PER. "This educational activity will outline the use of patient- and disease-specific characteristics to inform clinical decision-making in the management of patients with genitourinary malignancies along with discussing current strategies and practice-changing evidence for the management of patients across multiple lines of care through many interactive sessions."

The New York GU (NYGU) congress is a two-day educational meeting that provides clinicians with valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies. During the congress, faculty experts will review the latest advances in the management of genitourinary malignancies and the optimal use of chemotherapeutic and local therapies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals and immunotherapies. Coverage will also include discussions of prognostic/predictive marker application and proactive mitigation of predictable treatment-related side effects. Attendees will also be able to address key concerns regarding the application of landmark clinical trial data (for example, prostate specific antigen screening and decision-making for castrate-sensitive prostate cancer).

This live activity is accredited by the Accreditation Council for Continuing Medical Education for 12.75 AMA PRA Category 1 Credits for physicians. For more information and to register, click here.

On February 18, 2019 Oncopeptides AB (Nasdaq Stockholm, ONCO) reported that the Company will release its Year-end Report on 22 February at 8:00 am CET (Press release, Oncopeptides, FEB 18, 2019, View Source [SID1234533530]). The report will be available on the Company’s web site at www.oncopeptides.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s CEO Jakob Lindberg will summarize the financial year 2018 and address questions from investors, analysts and media at 14:00 CET, 22 February.

An audiocast to the presentation will be available at:

View Source

Time for webcast – 14:00 (CET) on 22 February
Dial in number from Sweden: +46856642706
Dial in number from UK: +443333009270
Dial in number US: +18335268382

On February 18, 2019 Xspray Pharma AB reported the results of a clinical Phase I pilot study with its HyNap-Sora drug candidate (Press release, Xspray, FEB 18, 2019, View Source [SID1234649548]). The study examined HyNap-Sora’s bioavailability compared to the sorafenib cancer drug, currently marketed as Nexavar for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Both investigated HyNap compositions demonstrated significantly increased bioavailability. The variability between subjects in AUC and Cmax was reduced to half compared to Nexavar for one of the HyNap-Sora formulations.
In the completed Phase I clinical trial in 14 healthy subjects, bioavailability of two different formulations of HyNap-Sora was assessed in comparison with Nexavar. The results are positive and the study achieved its primary purpose to show increased bioavailability compared to the originator product. In addition, and as shown in earlier studies with Xspray’s lead product candidate, HyNap-Dasa, the study also showed reduced between subject variability.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Sorafenib has a very different pharmacokinetic profile than our product candidates based on nilotinib and dasatinib. Therefore, I’m very pleased that we achieved the primary purpose of this study with sorafenib which enables continuation of the development program. It confirms and strengthens our belief that HyNap formulations of PKIs have the potential to improve both present and upcoming products with poor solubility, improving efficacy and safety enhancing patients’ quality of life during this type of therapy," says Per Andersson, CEO of Xspray.

The clinical results in summary:

• The HyNap formulations were administered at half the dose compared to Nexavar to account for expected increase in bioavailability

• Area under the curve (AUC) was approximately 80 % for the HyNap-Sora formulations compared to Nexavar, indicating that the bioavailability of Sorafenib from HyNap-Sora was 1.6-fold higher

• The maximum concentration of Sorafenib in plasma (Cmax) was approximately 95 % compared to Nexavar.

• The variability between subjects in AUC and Cmax was reduced to half compared to Nexavar for one of the HyNap-Sora formulations.

Sorafenib is a compound with low aqueous solubility and low bioavailability from the sorafenib tablet (Nexavar). The present study demonstrates that the HyNap technology can increase the extent of absorption of sorafenib and reduce between subject variability by improving the solubility.